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In human immunodeficiency virus (HIV)-infected patients treated with potent antiretroviral therapy, the
persistence of latently infected cells may reflect the long decay half-life of this cellular reservoir or ongoing viral
replication at low levels with continuous replenishment of the population or both. To address these possibil-
ities, sequences encompassing the C2 and V3 domains of HIV-1 env were analyzed from virus present in
baseline plasma and from viral isolates obtained after 2 years of suppressive therapy in six patients. The
presence of sequence changes consistent with evolution was demonstrated for three subjects and correlated
with less complete suppression of viral replication, as indicated by the rapidity of the initial virus load decline
or the intermittent reappearance of even low levels of detectable viremia. Together, these results provide
evidence for ongoing replication. In the remaining three patients, virus recovered after 2 years of therapy was
either genotypically contemporary with or ancestral to virus present in plasma 2 years before, indicating that
virus recovery had indeed resulted from activation of latently infected cells.
Treatment with combination antiretroviral agents can re-
duce plasma and lymph node RNA levels below the level of
detection of sensitive assays for nucleic acid (2, 12, 31, 46). The
persistence of cells harboring replication-competent virus de-
spite periods of up to 3 years of potent suppressive therapy has
raised questions about the feasibility of eradication of infection
with currently recommended treatments (3, 9, 10, 47, 49). De-
spite the apparent lack of development of drug resistance in
patients with undetectable virus (9, 47), the inferred presence
of unintegrated viral DNA in peripheral blood mononuclear
cells (PBMC) in one study (3) has raised questions about the
certainty that viral replication is controlled even in this setting.
Extrapolating from such observations, it can be argued that the
persistence of this reservoir of virus reflects ongoing viral rep-
lication at low levels and continuous replenishment rather than
the existence of long-lived, latently infected cells.
To address this question, we studied sequences of the human
immunodeficiency virus type 1 (HIV-1) envelope correspond-
ing to the relatively conserved C2 and the hypervariable V3
domains of env from HIV-1 present in baseline plasma and in
virus recovered from in vitro culture of PBMC following 2
years of therapy. The V3 region is an important determinant of
cell tropism and is a target of host immune responses. Conse-
quently, it is among the most variable regions in the HIV
genome (15, 19, 21, 36). Sequence differences in this region
have been used to compare the relatedness of virus popula-
tions (20, 33, 42) and to study viral evolution within individual
hosts (1a, 6, 37–39, 45), among patients (1a, 6, 25, 26, 37, 38,
45), and across patient populations (21, 22, 27).
Samples were studied from six individuals from whom, de-
spite prolonged suppression of plasma viremia, virus had been
previously recovered by coculture of PBMC (47). We hypoth-
esized that ongoing replication should be accompanied by
changes in viral envelope sequence and that phylogenetic anal-
ysis would permit the distinction of virus produced by activa-
tion of latently infected cells from that produced as a conse-
quence of continued viral propagation during the course of
therapy.
(Presented in part at the 2nd International Workshop on
HIV Drug Resistance and Treatment Strategies, Lake Mag-
giore, Italy, June 1998.)
MATERIALS AND METHODS
Patient selection. Subjects were chosen from a well-characterized cohort of
HIV-infected patients undergoing treatment with indinavir, lamivudine, and
zidovudine (12, 47). Each had apparent suppression of plasma and serum viral
RNA to below the 50-copy/ml level with the exception of patient M, who had 50
copies of HIV RNA/ml on the day of PBMC sampling for virus isolation (Fig. 1).
Sequence comparisons were made between virus present in baseline plasma and
virus isolated while on drug therapy at year 2.
Viral isolates. The materials and methods for viral isolation have been previ-
ously published (47). Early culture supernatants were chosen to minimize ex vivo
culture effects on the composition of the viral isolates (typically at day 14 of
original cultures and before peak p24 production).
RNA extraction. RNA was extracted from cell-free viral culture supernatants
with the Qiagen HCV RNA extraction kit (Qiagen, Chatsworth, Calif.) and from
plasma by the AMPLICOR extraction procedure (Roche Diagnostics, Branch-
burg, N.J.) according to the manufacturers’ protocols.
RT-PCR. Following denaturation of the RNA template and primer mix at
70°C for 3 min, reverse transcription (RT) was performed at 45°C for 1 h in the
following buffer: 100 mM Tris (pH 8.3), 10 mM MgCl, 50 mM KCl, 10 mM
dithiothreitol, 250 mM dinucleoside triphosphate, 37 U of RNAgard (Pharma-
cia), 2.5 U of avian myeloblastosis virus reverse transcriptase (Gibco BRL,
Gaithersburg, Md.), 12.5 pmol of V3Bout primer (59-ATTACAGTAGAAAAA
TTCCCCT-39). Nested PCRs were then performed in quadruplicate for each
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sample to minimize sampling bias. RT product (cDNA; 10 ml) was carried over
to a first-step PCR employing the primers V3Bout and V3Fout (59-CAAAGG
TATCCTTTGAGCCAAT-39) under the following reaction and thermocycling
conditions: Tris (pH 8.3), 3 mM MgCl2, 250 mM deoxynucleoside triphosphate,
20 pmol of primers, 1 mg of bovine serum albumin/ml, 5 U of Taq polymerase
(Boehringer Mannheim) in a 50-ml reaction volume at 95°C for 2 min, 95°C for
30 s, 55°C for 30 s, 72°C for 1 min for 35 cycles; and 72°C for 1 min. One
microliter of the first-step product was then carried over to a second-step PCR
with the primers V3Fin (59-GAACAGGACCAGGATCCAATGTCAGCACAG
TACAAT-39) and V3Bin (59-GCGTTAAAGCTTCTGGGTCCCCTCCTGAG-
39) with reaction conditions identical to those for the first-step PCR. Ten percent
of the PCR products were resolved on 1% agarose gels and visualized by
ethidium bromide staining. We have examined the rate of misincorporation
during amplification under these nested PCR conditions by comparing the re-
sults from sequencing of unamplified pNL4-3 (1) with those from sequencing of
amplified and subsequently cloned products and have observed a misincorpora-
tion frequency of approximately 1 to 3 per 3,500 bases.
Cloning. After determination that each of quadruplicate nested PCR products
yielded comparable band intensities by ethidium staining, 5 ml of each of the
quadruplicate reactions were pooled together and gel purified by agarose gel
electrophoresis. DNA was extracted from gel slices with the Qiaex II Gel Ex-
traction kit (Qiagen) according to the manufacturer’s protocol. Two microliters
of the pooled, gel-purified PCR products was ligated into the plasmid vector
pCR 2.1 and cloned according to the instructions for the TOPO Ta Cloning
system (Invitrogen, Carlsbad, Calif.) under ampicillin selection.
Sequencing. Ten to 13 individual clones were picked based on blue-white
screening and grown in 3-ml cultures. Plasmids were purified with the Qiaprep
Turbo-8 kit (Qiagen). Approximately 300 ng of each plasmid was sequenced with
the sequencing primers ForTopoEcoR1 (59-TGGATATCTGCAGAATTCG-39)
and M13 Reverse (59-CAGGAAACAGCTATGAC-39) with a 373A automated
sequencer and Big-dye chain terminator chemistry (Applied Biosystems, Inc.,
Foster City, Calif.). The sequences were aligned and manually edited with Se-
quence Navigator 1.1 (Applied Biosystems). In total, 115 evaluable sequences
were obtained for the six patients.
Phylogenetic analysis. Tree reconstructions were performed by a neighbor-
joining method implemented with DNADIST (Kimura distances; transition
transversion ratio, 2.0) and NEIGHBOR in Phylip version 3.54 (7) with 100
bootstrapped data sets and by a maximum-likelihood method with fastDNAML
(7, 30), applying a transition/transversion ratio of 2.0 and a uniform substitution
rate. Graphic representation of phylogenetic trees was accomplished with Tree-
view version 1.5 (30a).
Determination of pairwise distances. Pairwise distances from the most recent
common ancestor (MRCA; represented by the most distal node which gives rise
to all sequences from the same patient) to clonal sequences on the maximum-
likelihood phylogenetic tree were estimated both by summing relevant branch
lengths generated with fastDNAML version 1.0 (random input order; transition/
transversion ratio, 2.0; single rate of substitution) (7, 30) and by direct compu-
tation with DNADIST (PHYLIP version 3.54; maximum-likelihood estimates;
transition/transversion ratio, 2.0) (7) from the inferred MRCA sequences ob-
tained with DNAML (PHYLIP version 3.6) (7, 8). Branch lengths from
fastDNAML were chosen over those provided by DNAML (PHYLIP version
3.6) because the latter presently assigns a minimum distance of 0.00005 to every
segment of inferred maximum-likelihood trees, including branches connecting
identical sequences. However, the two programs produced trees with comparable
maximum-likelihood values. Duplicate analyses were performed, with selection
of the MRCA based on all viral isolate sequences and the nearest plasma
sequences (changed the selection of the MRCA for patients A, C, and M).
Means and standard errors for distances were calculated with JMP version 3.1.5
(SAS, Cary, N.C.).
Mean pairwise distances between plasma virus and viral isolates were calcu-
lated with the program SENDBS (Naoko Takeaki) with and without correcting
for within-sample diversity (29).
Estimation of residual replication. Residual HIV replication was approxi-
mated by calculation of the area under the curve (AUC) generated by plotting
log plasma RNA against time. The observed AUC (AUCObs) represented the log
RNA copy by time product which results from the decay of free virus in plasma
and virus produced by cells infected prior to institution of therapy (productively
infected cells; a reservoir of “long-lived” infected cells; and release of virus from
the follicular dendritic network in lymphoid tissues and activation of latently
infected cells) as well as from any virus produced as a consequence of ongoing
viral replication during combination therapy.
The theoretical AUC for each patient was estimated according to the long-
lived-infected-cell model of Perelson et al. (31). This calculation assumes decay
FIG. 1. Log RNA copies/ml in serum or plasma plotted against days under
indinavir, zidovudine, and lamivudine combination therapy. The baseline for the
y axis is the limit of detection of the Roche ultrasensitive assay (1.6 log copies/
ml). The top panel demonstrates the response of two patients (Pt.) with steep
initial declines in viral load (A and B). The middle panel shows two patients with
steep initial declines followed by transient reappearance of low levels of detect-
able viral RNA (K and L). The bottom panel shows two patients with slow initial
responses (C and M) and, in one patient (M), intermittent transient reappear-
ance of low levels of viral RNA in the blood.
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in the absence of residual viral replication under therapy and assumes that
activation of latent cells contributes relatively little to the viral RNA measured
during first- or second-phase decay of plasma virus. Log10 viral RNA copy
number (log10V) as a function of time (t) can be described as follows:
log10V~t! 5 log10V0S@NkT0/~c 2 d!#e2dt 1 @~c 2 NkT0!/~c 2 mM!#e2mMt 1 {1
2 @NkT0/~c 2 d!# 2 @~c 2 NkT0!/~c 2 mM!#}e2ctD (1)
where V0 is the viral load at baseline, d is the decay constant of productively
infected cells, mM is the decay constant of long-lived cells, c is the clearance
constant for virions, T0 is the CD4 count at baseline, N is the viral burst size, and
k is the infection constant (31). Perelson et al. observed NkT0 values between
2.84 and 2.92 for a T0 of 205 to 500 cells/mm3. We utilized a mean value for NkT0
of 2.88 and the observed virus clearance constant, c, of 3 day21 in our analysis
(32).
The serially measured viral RNA concentrations and those calculated from
equation (1) were plotted against time under treatment with the program
PRISM 2.0 (Graphpad, San Diego, Calif.). AUCs were calculated by summation
of trapezoids implemented in the program PRISM 2.0. The predicted AUC
(AUCPred) was computed with a d of 1.2 day21 and a mM of 0.115, based on the
best-case decay constants observed by Perelson et al. (31). Duplicate analyses
with a d of 0.7 day21 and a mM of 0.066 based on mean decay constants (31) for
the calculation of AUCPred resulted in very similar results (data not shown). The
difference between AUCObs and AUCPred, then, represented the proportion of
the RNA concentration by time product that should be attributable to residual
viral replication for each patient while under therapy (AUCNet).
In general, the use of AUC as an indicator of the difference in the degree of
ongoing viral replication between patients may be best when their baseline RNA
concentrations are similar, while the calculation of AUCNet from AUCObs and
AUCPred becomes most necessary when baseline RNA concentrations vary
greatly among the patients being compared. In the present study, the patients
had relatively uniform starting RNA levels.
Our calculations assumed negligible contribution to total viremia from spo-
radic activation of latently infected cells (a simplification justified by observations
of phase 1 and phase 2 decay by Perelson et al. [31]) and may therefore tend to
underestimate the AUCPred, leading to overestimates of AUCNet. Because of this
and other assumptions made for the derivation of these terms, it would be
incorrect to treat the calculated values as definitive for residual viral replication.
Rather, they are meant to represent a relative magnitude of residual replication
(derived from the best available kinetic data and based on prevailing theory in
the published literature) and are applied here to permit reasonable interpatient
comparison.
Statistical analyses. Correlations of AUCNet with pairwise genetic distance
and Wilcoxon rank sums for comparison of pairwise distances were computed
with the statistical analysis program JMP 3.1.5. (SAS) and the program Prism 2.0.
Nucleotide sequence accession numbers. All sequences reported here have
been deposited in GenBank and were given accession no. AF185823 to
AF185937.
RESULTS
Assessment of residual viral replication based on the re-
sponse of serum and plasma RNA to drug therapy permitted
segregation of the patients into three patterns (Fig. 1). Group
1 (patients A and B) had subjects with the steepest initial
declines in viral load and without any detectable viral RNA for
the duration of this study period. Group 2 patients (K and L)
were subjects who had similarly rapid initial declines in plasma
virus concentrations upon initiation of therapy but with spo-
radic reappearance of low but detectable levels of viremia
later. Finally, two patients (C and M) constituted a third group
exhibiting a protracted and gradual decline in plasma virus
levels with later sporadic reappearance of viremia throughout
the first 2 years of therapy. In the case of M, viral RNA was
present in plasma at the same time that samples were obtained
for viral culture (47). The amount of residual replication as
reflected by AUCNet was low to negligible for patients A, B,
and L, intermediate for K and C, and highest for patient M
(Table 1).
Phylogenetic reconstruction. In every case, sequences from
each patient clustered together and not with those from other
patients or with prototypic laboratory-adapted and “primary”
HIV clones, as shown by a reconstruction by maximum-likeli-
hood analysis (Fig. 2) (24). Tree topology with a neighbor-
joining reconstruction was similar: sequences from each pa-
tient formed individual clusters with highly significant
bootstrap values (.80 per 100 bootstrapped data sets exam-
ined) in the consensus neighbor-joining tree (data not shown).
In one case (patient B), year 2 isolates were indistinguishable
from sequences present at baseline and were very homoge-
neous. For patients A and C, the viral isolates most closely
resembled one or a subset of sequences present in baseline
plasma, while for patients K, L, and M, no plasma sequences
were identified which clearly clustered with sequences from
year 2 viral isolates, although in the case of M, a “nearest
plasma clone” could be identified. For patients M and C,
branch lengths from the closest proximal common node (rep-
resenting the most recent common ancestor) to the year 2
isolates appeared longer than those to the baseline plasma
sequences.
Protein sequence comparisons. In four patients, inferred
protein sequences demonstrated little difference between base-
line and year 2 isolates in the C2 region (Fig. 3). In the V3
region, baseline sequences differed from year 2 viral isolates at
multiple positions in the case of patient M, while few differ-
ences were noted for the other five subjects. For patient M, an
S-to-R substitution was seen at position 306 (according to
HXB2 sequence by convention of the Los Alamos National
Laboratories) in the V3 loop which has been associated with a
switch from M- to T-cell tropism (4, 11), but cell tropism and
presumably coreceptor usage are context dependent (40). In
this patient there was an accompanying R-to-S replacement at
residue 322. Cultivation of the year 2 virus in an MT-2 cell
assay (34) showed that it was non-syncytium inducing (data not
shown). In the case of patient K, multiple replacements were
noted in the region downstream from the V3 loop, towards V4.
Pairwise genetic distances between baseline plasma virus
and year 2 viral isolates. Pairwise genetic distances (both cor-
rected and uncorrected for overall diversity of clones from
each source) demonstrated a continuum of small but measur-
able distances between baseline plasma-derived sequences and
2-year viral isolates. Corrected distances demonstrated consid-
erably greater variability than uncorrected ones due to sub-
stantial variation among patients in the level of diversity in
plasma samples (Table 2). A more conservative calculation of
net divergence was also made by using the diversity of the time
zero plasma population as an estimate of the true diversity of
virus in the population of viably infected cells at year 2. The
rank orders of divergence in these analyses were similar, with
M and K showing the greatest divergence (data not shown).
TABLE 1. Residual viral replicationa
Patient AUCObs AUCPred AUCNet
A 70.74 43.90 26.84
B 71.49 27.24 44.25
L 54.81 24.13 30.68
K 97.60 36.81 60.79
C 194.3 40.97 153.33
M 276.1 40.47 235.63
a Log10 RNA copies/ml 3 day products for each patient grouped according to
pattern of RNA response following initiation of therapy (Fig. 1). The AUCs were
calculated with a baseline equal to the threshold of sensitivity of the Roche
ultrasensitive assay, 1.6 log10 RNA copies/ml. AUCObs is the product obtained
from the measured values plotted in Fig. 1. AUCPred was calculated based on a
mathematical model from Perelson et al. using the best-case decay constants
observed by Perelson. AUCNet is the difference between AUCPred and AUCObs
and represents the proportion of the AUC that may reflect ongoing viral repli-
cation and/or production of virus from activation of latent cells (see the text).
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Genetic distance to MRCA. Based on coalescence theory
(17, 18, 35, 41), each sequence can be traced back to the most
recent common ancestral sequence (the MRCA, represented
by the most distal node common to all sequences from each
patient on the phylogenetic tree [Fig. 2]), with branch lengths
proportional to the number of elapsed generations. Here we
assume that the mutation rate m is relatively constant among
individuals so that sequence divergence is determined by gt,
where g is the number of generations (replication cycles) times
time21 and t is the elapsed time. Although mutations within
the reverse transcriptase have been reported to affect the fi-
delity of HIV-1 RT (43), such mutations were not observed in
these viral isolates (47).
The difference between mean genetic distances from year 2
viral sequences and those from year zero plasma sequences to
the MRCAs for each patient was calculated to provide a rel-
ative measure of generations elapsed since the common ances-
tor. Larger positive differences would be expected when year 2
isolates are more divergent from the MRCA than baseline
plasma virus, and increasingly more negative values would be
expected when the viral isolates are genealogically older than
baseline plasma virus (Table 3). When MRCAs for each pa-
tient were identified based on all available sequences, the dis-
tances from the MRCA to year 2 viral isolates exceeded the
distances from the MRCA to the baseline plasma sequences
derived by summation of branch lengths for three patients (M
[P 5 0.0006 for Wilcoxon rank sum], C [P 5 0.001], and K [P 5
0.0208]), were equivalent for one (A [P 5 0.667]) and were less
for two (B [P 5 0.0023] and L [P 5 0.0002]) subjects. The
results were qualitatively similar for distances generated by
direct calculation of distance from inferred and observed se-
quences, although the differences only approached borderline
significance for K and were not significant for L and C (Table
3). Analysis based on MRCAs selected for the year 2 viral
isolate clusters and the single plasma clone nearest each year 2
cluster gave comparable results (data not shown).
Both the summation of branch length method and the direct
estimation of distances were based on results from phyloge-
netic reconstruction. As such, they reflect the accuracies and
limitations of these methods (7, 16). In the case of analysis
of branch lengths, the individual branch lengths given by
fastDNAML were typically associated with fairly wide confi-
dence intervals. The confidence intervals for the segments con-
necting the root of the year 2 viral isolate clusters and either
the nearest plasma sequence (patients A, C, and M) or the root
of plasma sequence clusters (B, K, and L) to the MRCA are
shown in Table 4.
Correlation of evolutionary distance with residual replica-
tion represented by AUCNet. Mean pairwise distances between
plasma virus and virus isolated at year 2 (both corrected and
uncorrected for intracompartment diversity) correlated with
AUCNet, with r
2 values of 0.55 and 0.6, respectively, but P
values only approached statistical significance (0.09 and 0.067,
respectively). However, differences in mean distance by anal-
ysis of branch lengths from MRCA to all virus isolates and to
all plasma sequences from the same patient showed a signifi-
cant correlation with AUCNet: r
2 5 0.889 (P 5 0.0048). Using
a direct calculation from the inferred ancestral sequences, the
r2 value was 0.68 (P 5 0.043) with AUCNet (Fig. 4). When
MRCAs were selected based on all viral isolates but only the
nearest plasma sequence(s) for each patient, similar correla-
tions were noted (data not shown).
DISCUSSION
Latently infected resting T cells harboring replication-com-
petent virus persist in treated patients despite the absence of
detectable free virus in the blood (3, 9, 47). Whether this
reservoir of virus is maintained as a result of a low level of
ongoing viral replication or as a result of a slow decay rate
carries important implications for the risk of development of
drug resistance and treatment failure in such patients. This
question is central to the success or failure of any eradication
strategy based on currently available antiviral drugs.
By conventional measures, all subjects studied had excellent
responses to therapy, with viral loads rapidly falling to below
200 copies/ml of serum or plasma upon initiation of antiviral
FIG. 2. Maximum-likelihood phylogenetic tree displaying relationships of
sequences of clones derived from plasma collected at the start of therapy (time
zero) and from viral isolates obtained approximately 2 years into therapy. The
letters adjacent to individual sequence clusters identify the patient source of the
sequences. In every case, the sequences from an individual patient clustered with
sequences from the same patient and with no others. Sequences of prototypic
T-lymphocytotrophic and macrophage-tropic viruses are denoted by the respec-
tive reference names (NL4-3, SF162, etc.). Sequences derived from baseline
plasma are represented by solid circles. Sequences derived from viral isolates are
indicated by open circles. The arrows with solid arrowheads identify nodes
representing the MRCA identified for all plasma and viral isolate sequences
from each patient. The arrows with open arrowheads identify nodes representing
the MRCA for the viral isolate cluster and the plasma viral sequence(s) nearest
it. Horizontal branch lengths are scaled and correspond approximately to the
percent nucleotide differences between sequences and nodes. Sequences whose
branch lengths were not significantly different from zero are shown with col-
lapsed branches.
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therapy. These responses were sustained at levels below the
threshold of detection of a more sensitive assay (,50 copies/
ml) for periods approaching 2 years at the time virus was
isolated (12, 13). Previous studies of these subjects had dem-
onstrated the lack of development of new genotypic drug re-
sistance over this period (47). However, a detailed examination
of the serial HIV RNA levels in blood from these patients
revealed varying patterns based on rapidity of decline of the
viral load and in some cases on the intermittent reappearance
of low-level viremia during the course of therapy. These qual-
itative differences were reflected quantitatively in the calcu-
lated AUCNet values representing residual viremia from ongo-
ing viral replication (and/or, to a small extent, from activation
of latently infected cells in vivo [see Materials and Methods]).
It is not known why the antiviral drug effect may vary among
these patients in spite of identical therapies, similar prestudy
drug treatment histories, and similar incidence of preexisting
drug resistance (13, 46, 47). Such differences could be attrib-
utable to individual differences in drug absorption or drug
metabolism or to variable adherence.
Pairwise genetic distances from year 2 viral isolates to cor-
responding baseline plasma virus and pairwise distances from
year 2 viral isolates and baseline plasma virus to the ancestral
sequence inferred from a maximum-likelihood phylogenetic
reconstruction were examined to estimate viral evolution in
these subjects. Use of simple pairwise distances from year 2
viral isolates to baseline plasma virus would be expected to be
an accurate reflection of generations elapsed between time
points if year 2 viral isolates were, in every case, descendent
from the virus present in plasma at baseline. However, if viral
isolates at year 2 arise from latently infected cells that might
have been ancestral to those present in plasma at baseline or
which might have descended independently from a common
ancestor, simple pairwise distances and generations elapsed
need not be directly proportional. So, while those three pa-
tients (C, K, and M) having the largest AUCNet (e.g., those
with slower initial decline of viremia and those with sporadic
reappearance of viremia) had the highest mean pairwise dis-
tances and the three subjects (A, B, and L) with the lowest
AUCNet had the lowest pairwise distances, the correlation of
these parameters failed to reach statistical significance.
To quantitatively analyze genetic relationships of virus iso-
lated at year 2 and virus present in baseline plasma (time zero)
without having to assume that year 2 virus descended directly
from baseline plasma virus, we examined pairwise distances
from each cloned sequence to the corresponding MRCAs. The
approach of summing relevant branch segments benefits from
F
IG
.
3.
Pr
ed
ic
te
d
pr
ot
ei
n
se
qu
en
ce
s.
A
ll
le
tt
er
de
si
gn
at
io
ns
fo
r
am
in
o
ac
id
s
(A
A
)
co
nf
or
m
to
th
e
st
an
da
rd
In
te
rn
at
io
na
l
U
ni
on
of
Pu
re
an
d
A
pp
lie
d
C
he
m
is
tr
y
co
de
.T
he
H
X
B
2
re
fe
re
nc
e
se
qu
en
ce
(L
os
A
la
m
os
N
at
io
na
lL
ab
or
at
or
y)
is
gi
ve
n
at
th
e
to
p
w
ith
th
e
re
gi
on
co
rr
es
po
nd
in
g
to
th
e
V
3
lo
op
m
ar
ke
d
by
a
he
av
y
lin
e
an
d
re
si
du
es
30
6
an
d
32
2
id
en
tifi
ed
w
ith
ar
ro
w
s.
Su
bj
ec
t
an
d
so
ur
ce
ar
e
id
en
tifi
ed
in
th
e
fir
st
co
lu
m
n,
w
ith
th
e
co
ns
en
su
s
se
qu
en
ce
in
pl
as
m
a
at
ba
se
lin
e
gi
ve
n
in
its
en
tir
et
y
(b
as
ed
on
th
e
m
os
tf
re
qu
en
tly
oc
cu
rr
in
g
A
A
at
ea
ch
po
si
tio
n,
or
w
he
n
tw
o
A
A
oc
cu
rr
ed
w
ith
eq
ua
lf
re
qu
en
cy
fr
om
th
e
sa
m
e
so
ur
ce
,t
he
A
A
co
rr
es
po
nd
in
g
to
th
e
H
X
B
2
re
fe
re
nc
e
at
th
e
sa
m
e
po
si
tio
n)
.S
ho
w
n
ne
xt
ar
e
cl
on
al
se
qu
en
ce
s
fr
om
ye
ar
0
pl
as
m
a,
fo
llo
w
ed
by
th
e
co
ns
en
su
s
se
qu
en
ce
fr
om
th
e
ye
ar
2
vi
ra
li
so
la
te
s
an
d
th
e
cl
on
al
se
qu
en
ce
s
fr
om
ye
ar
2
vi
ra
li
so
la
te
s.
T
he
se
se
qu
en
ce
sa
re
sh
ow
n
w
ith
th
e
fo
llo
w
in
g
ab
br
ev
ia
tio
ns
in
re
fe
re
nc
e
to
th
e
ba
se
lin
e
pl
as
m
a
co
ns
en
su
ss
eq
ue
nc
e
fo
rt
he
sa
m
e
pa
tie
nt
:p
er
io
d,
id
en
tit
y
w
ith
th
e
pl
as
m
a
co
ns
en
su
s;
da
sh
,g
ap
in
se
rt
ed
to
m
ai
nt
ai
n
al
ig
nm
en
t
of
al
l
se
qu
en
ce
s
sh
ow
n;
qu
es
tio
n
m
ar
k,
un
re
so
lv
ed
A
A
po
si
tio
n;
as
te
ri
sk
,
no
ns
en
se
m
ut
at
io
n.
R
ep
la
ce
m
en
ts
ar
e
in
di
ca
te
d
by
th
e
ap
pr
op
ri
at
e
co
de
le
tt
er
.
T
he
fr
eq
ue
nc
y
w
ith
w
hi
ch
a
pa
rt
ic
ul
ar
cl
on
al
se
qu
en
ce
w
as
en
co
un
te
re
d
is
sh
ow
n
in
th
e
fir
st
co
lu
m
n
ad
ja
ce
nt
to
ea
ch
se
qu
en
ce
.F
or
pa
tie
nt
M
,r
es
id
ue
s
30
6
an
d
32
2
ha
ve
be
en
bo
xe
d
to
hi
gh
lig
ht
th
e
su
bs
tit
ut
io
ns
no
te
d.
TABLE 2. Pairwise genetic distances between baseline plasma virus
and year 2 viral isolatesa
Patient
Pairwise distance
(uncorrected)
(%)
Pairwise distance
(Nei and Tajima
correction) (%)
A 3.76 1.37
B 0.25 0.0005
L 2.0 0.92
K 3.54 3.18
C 3.46 1.51
M 7.19 4.96
a Pairwise genetic distances between sequences in plasma at time zero and
viral isolates at 2 years. In increasing order, the uncorrected estimates of diver-
gence are B ,, L , C, K, A ,, M. The corrected estimates are much more
variable than the uncorrected estimates (coefficient of variation, 0.68 for the
uncorrected estimates and 0.90 for the corrected estimates). In increasing order,
the corrected estimates of divergence are B ,, L, A, C , K , M.
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the incorporation of the structure of the inferred phylogenies
into the distance measurements but does not readily yield an
appropriate confidence interval. Therefore, we have also re-
constructed the MRCA sequences with a maximum-likelihood
approach (implemented in PHYLIP version 3.6) (7, 8) and
directly estimated evolutionary distance between these and the
baseline (plasma) and year 2 (virus isolate) sequences. The
estimates resulting from both of these approaches demon-
strated significant correlations of differences in distance to the
MRCA with AUCNet (Fig. 4).
Findings consistent with sequence evolution in cultured virus
from some patients but not from others could be explained by
a sampling artifact (isolation of virus from few latently infected
cells) or by a selection artifact from in vitro coculture condi-
tions with some patients but not others (5, 23, 28). We have
analyzed sequences of virus cultured at time zero from patient
A (virus isolates from time zero were not available from the
other patients). This baseline isolate clustered more closely
with virus in plasma at time zero than with viral isolates from
the year 2 time point (data not shown), indicating greater
effects from the time of sampling than from in vitro culturing
in this setting. Moreover, the strong correlation between se-
quence evolution (measured by pairwise distances to the
MRCA) and residual replication inferred by the magnitude of
AUCNet supports in vivo biological differences over random
sampling artifacts or artifacts from in vitro culture to explain
these differences. Additional studies of the nature of the se-
quence changes observed have been performed which show
that in the cases of M and K, but not the other four subjects,
the changes in fact reflect selective differences between year 0
and year 2 (11a).
In the case of patient M and possibly patient K, the inter-
mittent appearance of detectable plasma viral RNA into the
TABLE 3. Genetic distances to MRCAsa
Patient Method
MRCA-to-base plasma
virus distance 6 SE
(%)
No. of clones
analyzed
MRCA-to-year 2 viral
isolate 6 SE (%)
No. of clones
analyzed
Wilcoxon
rank sum (P)
Difference mean
branch lengths
to MRCA
A BL 4.194 6 0.287 9 4.062 6 0.273 10 0.667 20.132
DD 3.892 6 0.226 4.210 6 0.238 0.44 0.318
B BL 0.233 6 0.043 10 0.022 6 0.037 13 0.0023 20.21
DD 0.232 6 0.043 0.022 6 0.037 0.0023 20.21
C BL 3.345 6 0.427 9 5.491 6 0.427 10 0.001 2.146
DD 2.696 6 0.164 2.731 6 0.164 0.507 0.035
K BL 1.67 6 0.089 7 1.924 6 0.074 10 0.0208 0.254
DD 1.677 6 0.092 1.912 6 0.077 0.07 0.235
L BL 2.16 6 0.142 10 0.114 6 0.135 10 0.0002 22.046
DD 1.67 6 0.141 1.276 6 0.134 0.112 20.39
M BL 2.72 6 0.166 10 6.56 6 0.198 7 0.0006 3.84
DD 2.584 6 0.272 5.251 6 0.326 0.0006 2.67
a Genetic distances to MRCA from plasma-derived sequences and year 2 viral isolates by summation of branch lengths (BL) generated with fastDNAML (7, 30) or
direct calculation from sequences (DD) generated with DNAML (PHYLIP 3.6) (7, 8). (The results shown are from analyses based on selection of an MRCA for all
plasma and viral isolate sequences.) The standard error (SE) was computed with a pooled estimate of error variance. Wilcoxon rank sums compare values to MRCA
from plasma virus with those from year two viral isolates. The difference of mean branch lengths to MRCA were computed by subtracting the mean plasma
virus-to-MRCA branch lengths from the mean year 2 viral isolate-to-MRCA branch lengths.
TABLE 4. Confidence intervalsa
Patient MRCA to baseplasma virus (%) (CI)
MRCA to year 2 viral
isolate (%) (CI)
A 0.585 (0, 1.404) 0.293 (0, 0.872)
B 0.0 (0, 0.558) 0.0 (0, 0.558)
C 0 (0, 0.722) 0.583 (0, 1.399)
K 1.466 (0.154, 2.81) 1.78 (0.342, 3.257)
L 0.864 (0, 1.853) 0.0 (0, 0.590)
M 0.570 (0, 1.392) 2.727 (0.953, 4.561)
a Branch lengths with confidence intervals (CI) of segments joining the root of
the plasma viral sequence(s) nearest the year 2 viral clusters with the MRCA
(identified based on the nearest plasma clone[s] and all year 2 viral isolate
sequences) (column 2) and joining the root of year 2 viral isolate clusters and the
same MRCA (column 3). The data were generated with fastDNAML (7, 30) and
correspond to the phylogenetic tree shown in Fig. 2.
FIG. 4. Regression analysis of the AUCNet and the differences in mean
distances from plasma virus and virus isolates to the MRCA with inclusion of all
plasma sequences calculated with summation of branch lengths (a) or by direct
calculation of distance from sequences (b). The solid line represents the line of
fit. The broken lines represent confidence curves for fit.
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second year of therapy and the finding of evolution in the
envelope sequences would be consistent with continuous or
intermittent viral replication. Alternatively, but not mutually
exclusively, in the case of patient M, where nonsynonymous
substitutions in V3 were so frequent, sequences of year 2 viral
isolates might reflect differences of a viral population main-
tained in an isolated anatomic compartment or a sanctuary site
(20, 33, 48, 49). For patient C, reappearance of detectable free
virus did not occur in the second year, although it was seen late
into the first year, and the initial decline of plasma viremia was
much more gradual than that seen for patient A, B, or L. In
this case, the intermediate level of sequence evolution ob-
served might be attributable either to viral replication occur-
ring soon after initiation of therapy or to low levels of ongoing
replication throughout the course of treatment.
Finally, in the cases of A, B, and L, treatment was associated
with both the rapid decay of plasma virus levels and the sus-
tained suppression of plasma viremia to undetectable levels. In
these subjects, corrected pairwise genetic distances between
sequences from baseline plasma and virus isolated later in
therapy were smaller. In these three cases, mean distances
from sequences of viral isolates at year 2 were equivalent to or
even shorter than mean distances from baseline plasma to the
MRCA, findings consistent with recovery of virus from cells
infected at the time of or before the baseline plasma se-
quences. However, the failure to demonstrate sequence evo-
lution for these patients in this particular viral reservoir does
not rule out the possibility that very low levels of replication or
replication in other compartments and in sanctuary sites not
accessible to drug therapy persist.
These findings have several important implications for the
understanding of HIV latency and the evaluation of antiviral
therapies. First, they confirm that, in subjects who have sus-
tained suppression of plasma viremia documented by the fre-
quent application of the most sensitive assays (such as patients
A, B, and L), a population of latently infected cells likely
persists into the third year of therapy and that the maintenance
of this reservoir of cells appears to be largely independent of
discernible viral replication. From the available data, one
would surmise that in such patients, the likelihood for emer-
gence of drug resistance should be small. Second, even among
patients who have apparent “suppression” of plasma viremia
based on less sensitive assays (thresholds between 50 and 200
copies/ml), a subset will not have achieved complete suppres-
sion of viral replication. In these cases, the reservoir of repli-
cation-competent virus (whether in latently or productively
infected cells) may in fact be replenished by continued viral
propagation, a conclusion consistent with the demonstration of
spliced RNA message and, in one case, changes seen in pol
sequences in subjects previously studied (14).
Frequent testing for viremia with the most sensitive assays
may permit the identification of such individuals with incom-
plete suppression of viral replication. The magnitude of risk for
development of drug resistance under these circumstances is
not known. Consequently, it is also not known whether, in the
absence of demonstrable drug resistance, additions to or sub-
stitutions in antiviral regimens are warranted. However, these
observations suggest that a less rapid initial decline in viral
load and the sporadic reappearance of low levels of detectable
viremia during therapy may signify incomplete suppression of
viral replication and that such assessments may be meaningful
in evaluating and comparing the potency of antiviral therapies,
as has been proposed by others (44). Finally, these findings
indicate that any measurement of the “clearance rate” of the
reservoir of latently infected T cells can only be accurately
performed on the very best characterized patients, employing,
at a minimum, both sensitive and frequent assays of residual
RNA in blood to screen for incomplete suppression of viral
replication.
ACKNOWLEDGMENTS
We gratefully acknowledge the technical assistance of Linda Terry
and Nancy Keating; the administrative assistance of Sharon Wilcox,
Darica Smith, and Mark Biedermann; and the participation of the
patients from the San Diego Cohort of M035. We further acknowledge
helpful comments and constructive criticism from Steven Wolinsky,
John Guatelli, James Mullins, Allen Rodrigo, Gerald Learn, Jon Con-
dra, and Lisa Frenkel and the cooperation of Emilio Emini, Leslie
Jonas, and Robin Isaacs.
This work was supported by NIH grants AI 01361 and AI 43752 and
a VA Career Development Award (J.K.W.); NIH grants AI 27670, AI
38858, and AI 29164 (D.D.R.); NIH grant AI 36214 (Center for AIDS
Research) (D.D.R. and D.J.L.); NIH grant RR 06555 (A.S.P.); Swiss
National Science Foundation Grant 84AD-046176 (H.F.G.); a Medical
Research Council grant (S.D.W.F.); an unrestricted educational grant
from the Merck Research Laboratories; and a grant from the Research
Center for AIDS and HIV Infection of the San Diego Veterans Affairs
Medical Center.
ADDENDUM
Following the submission of our manuscript, Zhang et al.
(50) reported the demonstration of viral replication in two of
eight patients with primary HIV infection treated with antiviral
therapy who had achieved undetectable plasma RNA levels. In
the same issue, Furtado and colleagues (11b) reported the
persistence of viral transcriptional activity in PBMC from
treated, chronically infected patients with undetectable viral
RNA, suggesting either ongoing replication or a transcription-
ally active form of latent infection.
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